# Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer

> **NCT00425386** · PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 60 (actual)

## Conditions studied

- Kidney Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** sunitinib malate
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00425386
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2010-08
- **Final completion:** 2014-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2017-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00425386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00425386, "Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00425386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*